Clearmind Medicine Inc (CMND)

$3.79 -0.19 (-4.77%)
Market Cap 4.06M
Revenue (ttm) 0.00
Net Income (ttm) -3.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,024,100
Avg Vol 2,541,883
Day's Range N/A - N/A
Shares Out 1.02M
Stochastic %K 62%
Beta 0.64
Analysts Strong Buy
Price Target N/A

Company Profile

Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as...

Industry: Biotechnology
Sector: Healthcare
Phone: 973 536 1016
Address:
1220 West 6th Avenue, Suite 101, Vancouver, Canada
StockScanners
StockScanners Jun. 9 at 4:31 AM
$CMND reached 4.13 from holding this level 3.56
0 · Reply
VK_10X
VK_10X Jun. 8 at 5:59 PM
Can $CMND do like $INHD …. Crazy move today
0 · Reply
jayjayup
jayjayup Jun. 8 at 4:14 PM
$CMND $QTEX $NEXR $GMHS $LASE is it me who is bad luck? fckn stocks aint goin up.. fk y’all
3 · Reply
EssTradesEss
EssTradesEss Jun. 8 at 3:22 PM
$CMND sold at 3.90. Was nit a fan of morning action so i am selling while up.
0 · Reply
Johnnytwofour2
Johnnytwofour2 Jun. 8 at 2:34 PM
$CMND Wasn't even that big a move. They are really quick on that halt trigger.
0 · Reply
VK_10X
VK_10X Jun. 8 at 2:33 PM
$CMND f***, that halt killed the momentum..
2 · Reply
Johnnytwofour2
Johnnytwofour2 Jun. 8 at 2:28 PM
$CMND 😂
0 · Reply
chbrkr2
chbrkr2 Jun. 8 at 2:27 PM
$CMND HALT
0 · Reply
Jjoulez89
Jjoulez89 Jun. 8 at 1:09 AM
$CMND Short idiots!
0 · Reply
Johnnytwofour2
Johnnytwofour2 Jun. 8 at 12:45 AM
$CMND Guys trying to sell this donw in the over night LMFAO. They have news coming out on Wednesday, the hype will keep this alive dummies. What do you think was happening Friday? Not basing? Its fine, gimme your cheap shares my buy orders are the ones your selling into. Damn fools.
0 · Reply
Latest News on CMND
Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar

Jun 5, 2026, 7:32 AM EDT - 3 days ago

Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar

Clearmind Medicine files Japanese patent application for 5-Methoxy-2-aminoindan

2026-05-29T13:48:45.000Z - 10 days ago

Clearmind Medicine files Japanese patent application for 5-Methoxy-2-aminoindan

Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment

May 29, 2026, 8:32 AM EDT - 10 days ago

Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment

Clearmind Medicine announces JHM-IRB approval to advance CMND-100 trial

2026-05-26T14:54:27.000Z - 13 days ago

Clearmind Medicine announces JHM-IRB approval to advance CMND-100 trial

Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts

May 26, 2026, 8:25 AM EDT - 13 days ago

Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts

Clearmind Medicine Inc trading halted, news pending

2026-05-20T23:55:09.000Z - 19 days ago

Clearmind Medicine Inc trading halted, news pending

Clearmind Medicine announces 1-for-10 reverse share split

2026-05-19T10:10:36.000Z - 21 days ago

Clearmind Medicine announces 1-for-10 reverse share split

Clearmind Medicine Announces 1-for-10 Reverse Share Split

May 19, 2026, 6:00 AM EDT - 21 days ago

Clearmind Medicine Announces 1-for-10 Reverse Share Split

Clearmind Medicine signs new research agreement with Yissum Research Development

2026-05-18T13:00:08.000Z - 21 days ago

Clearmind Medicine signs new research agreement with Yissum Research Development

Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications

May 18, 2026, 8:42 AM EDT - 21 days ago

Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications

Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.

May 15, 2026, 8:35 AM EDT - 24 days ago

Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.

Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder

May 12, 2026, 8:41 AM EDT - 27 days ago

Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder

Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial

May 11, 2026, 7:55 AM EDT - 4 weeks ago

Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial

Clearmind Medicine files European patent application for psychedelic compounds

2026-05-05T12:59:55.000Z - 4 weeks ago

Clearmind Medicine files European patent application for psychedelic compounds

Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD

May 5, 2026, 8:50 AM EDT - 4 weeks ago

Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD

Clearmind Medicine files to sell 22.63M common shares for holders

2026-04-30T21:03:58.000Z - 5 weeks ago

Clearmind Medicine files to sell 22.63M common shares for holders

Clearmind Medicine Registration statement: Registration filing

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Clearmind Medicine Registration statement: Registration filing

Clearmind announces evaluation of CMND-100 for breakthrough therapy designation

2026-04-27T11:48:40.000Z - 6 weeks ago

Clearmind announces evaluation of CMND-100 for breakthrough therapy designation

Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation

Apr 27, 2026, 7:41 AM EDT - 6 weeks ago

Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation

Clearmind Medicine Welcomes President Trump's Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care

Apr 20, 2026, 4:03 PM EDT - 7 weeks ago

Clearmind Medicine Welcomes President Trump's Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care

Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial

Apr 20, 2026, 7:15 AM EDT - 7 weeks ago

Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial

Clearmind announces DSMB recommendation to continue CMND-100 trial

2026-04-16T15:26:52.000Z - 7 weeks ago

Clearmind announces DSMB recommendation to continue CMND-100 trial

Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial

Apr 15, 2026, 7:30 AM EDT - 7 weeks ago

Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial

Clearmind Medicine's CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Apr 14, 2026, 7:32 AM EDT - 7 weeks ago

Clearmind Medicine's CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Mar 30, 2026, 8:32 AM EDT - 2 months ago

Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Mar 27, 2026, 7:32 AM EDT - 2 months ago

Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder

Mar 19, 2026, 8:45 AM EDT - 2 months ago

Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies

Mar 17, 2026, 9:15 AM EDT - 2 months ago

Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies

NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

Mar 16, 2026, 7:30 AM EDT - 3 months ago

NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

Mar 13, 2026, 7:45 AM EDT - 3 months ago

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

Clearmind Medicine Quarterly report: Q1 2026

Mar 12, 2026, 5:00 PM EDT - 3 months ago

Clearmind Medicine Quarterly report: Q1 2026

Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results

Mar 11, 2026, 9:07 AM EDT - 3 months ago

Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results

NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Mar 11, 2026, 7:30 AM EDT - 3 months ago

NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Mar 10, 2026, 8:59 AM EDT - 3 months ago

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

SPRC

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

Mar 4, 2026, 7:30 AM EST - 3 months ago

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?

Feb 19, 2026, 1:05 PM EST - 3 months ago

Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?

Clearmind Medicine Registration statement: Registration Filing

Feb 17, 2026, 7:00 AM EST - 3 months ago

Clearmind Medicine Registration statement: Registration Filing

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Feb 9, 2026, 8:17 AM EST - 4 months ago

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI

Feb 6, 2026, 7:55 AM EST - 4 months ago

Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI

Excellent Achievements for Clearmind's Proprietary MEAI that was Included in U.S. Congress' Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments

Feb 3, 2026, 8:00 AM EST - 4 months ago

Excellent Achievements for Clearmind's Proprietary MEAI that was Included in U.S. Congress' Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments

Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025

Jan 20, 2026, 4:20 PM EST - 4 months ago

Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025

Clearmind Medicine Annual report: Q4 2025

Jan 20, 2026, 7:00 AM EST - 4 months ago

Clearmind Medicine Annual report: Q4 2025

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

Jan 14, 2026, 8:55 AM EST - 5 months ago

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement

Dec 31, 2025, 9:10 AM EST - 5 months ago

Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement

Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth

Dec 24, 2025, 9:15 AM EST - 5 months ago

Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

Dec 16, 2025, 8:45 AM EST - 6 months ago

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment

Dec 12, 2025, 8:32 AM EST - 6 months ago

Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment

Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Dec 12, 2025, 6:32 AM EST - 6 months ago

Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Clearmind Medicine Announces 1-for-40 Reverse Share Split

Dec 10, 2025, 4:15 PM EST - 6 months ago

Clearmind Medicine Announces 1-for-40 Reverse Share Split

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Dec 5, 2025, 5:00 PM EST - 6 months ago

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Clearmind Medicine Registration statement: Registration Filing

Dec 5, 2025, 7:00 AM EST - 6 months ago

Clearmind Medicine Registration statement: Registration Filing

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder

Dec 2, 2025, 7:57 AM EST - 6 months ago

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial

Dec 1, 2025, 8:56 AM EST - 6 months ago

Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial

Clearmind Medicine Registration statement: Registration Filing

Nov 26, 2025, 7:00 AM EST - 6 months ago

Clearmind Medicine Registration statement: Registration Filing

Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial

Nov 25, 2025, 7:17 AM EST - 6 months ago

Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial

Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review

Nov 24, 2025, 8:51 AM EST - 7 months ago

Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review

Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site

Nov 20, 2025, 6:01 AM EST - 7 months ago

Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 19, 2025, 8:30 AM EST - 7 months ago

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

SPRC

Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Nov 18, 2025, 8:56 AM EST - 7 months ago

Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 17, 2025, 7:55 AM EST - 7 months ago

Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Nov 13, 2025, 8:54 AM EST - 7 months ago

Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment

Nov 12, 2025, 6:25 AM EST - 7 months ago

Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment

Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Nov 10, 2025, 8:07 AM EST - 7 months ago

Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Nov 6, 2025, 4:02 PM EST - 7 months ago

Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing

Nov 5, 2025, 6:55 AM EST - 7 months ago

Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing

StockScanners
StockScanners Jun. 9 at 4:31 AM
$CMND reached 4.13 from holding this level 3.56
0 · Reply
VK_10X
VK_10X Jun. 8 at 5:59 PM
Can $CMND do like $INHD …. Crazy move today
0 · Reply
jayjayup
jayjayup Jun. 8 at 4:14 PM
$CMND $QTEX $NEXR $GMHS $LASE is it me who is bad luck? fckn stocks aint goin up.. fk y’all
3 · Reply
EssTradesEss
EssTradesEss Jun. 8 at 3:22 PM
$CMND sold at 3.90. Was nit a fan of morning action so i am selling while up.
0 · Reply
Johnnytwofour2
Johnnytwofour2 Jun. 8 at 2:34 PM
$CMND Wasn't even that big a move. They are really quick on that halt trigger.
0 · Reply
VK_10X
VK_10X Jun. 8 at 2:33 PM
$CMND f***, that halt killed the momentum..
2 · Reply
Johnnytwofour2
Johnnytwofour2 Jun. 8 at 2:28 PM
$CMND 😂
0 · Reply
chbrkr2
chbrkr2 Jun. 8 at 2:27 PM
$CMND HALT
0 · Reply
Jjoulez89
Jjoulez89 Jun. 8 at 1:09 AM
$CMND Short idiots!
0 · Reply
Johnnytwofour2
Johnnytwofour2 Jun. 8 at 12:45 AM
$CMND Guys trying to sell this donw in the over night LMFAO. They have news coming out on Wednesday, the hype will keep this alive dummies. What do you think was happening Friday? Not basing? Its fine, gimme your cheap shares my buy orders are the ones your selling into. Damn fools.
0 · Reply
Stock_Catcher
Stock_Catcher Jun. 8 at 12:24 AM
Money Monday Watchlist Pt. 3 Continuation $STI $SCAG $DEVS $SMTK $CMND
0 · Reply
XkaliburTrading
XkaliburTrading Jun. 7 at 10:32 PM
Hello everyone! I hope you all had a great weekend with your family friends or loved ones 🙏 I am very ready for this week ahead but wanted to do a small recap of last Friday. The Team and I was able to spot these at... (Part 2) - Last Friday Recap $BESS at 4.73 hod at 10.40 💯% potential + $CMND at 2.89 hod at 4.87 💪 $DEVS at .495 hod at .70 🫡 $DAIC at 3.80 hod at 6.45 almost 🔥
0 · Reply
StockScanners
StockScanners Jun. 6 at 10:58 PM
$CMND 3.56 is the area I'm watching as this chart continues to develop. What stands out is the potential series of higher lows forming beneath the surface. When a stock begins tightening while gradually establishing higher support points, it can offer valuable insight into underlying participation. Often, the structure leading into a move is just as important as the move itself. Anyone else noticing the higher-low pattern taking shape here?
2 · Reply
TALENT_ON_LOAN_FROM_GOD
TALENT_ON_LOAN_FROM_GOD Jun. 6 at 5:21 PM
$BGMS THE MEDICAL WASTE PLANT WE’RE BUYING: https://www.futurenrg.net/medical-waste MONEYMADE $1.50 $CMND $ELOG $STI $SUGP
1 · Reply
BRDUPO
BRDUPO Jun. 6 at 5:17 PM
$CMND The dilution is epic.
0 · Reply
topstockalerts
topstockalerts Jun. 6 at 12:24 PM
Top Gainers PT2 $STI $BGMS $SUGP $ELOG $CMND
0 · Reply
topstockalerts
topstockalerts Jun. 6 at 12:52 AM
$CMND the path of least resistance appears to be higher.
0 · Reply
topstockalerts
topstockalerts Jun. 5 at 9:43 PM
Top Gainers PT2 $BGMS $SUGP $ELOG $CMND $SNBR
0 · Reply
R1cfla1rDr1p
R1cfla1rDr1p Jun. 5 at 9:34 PM
$NEXR 800k float flying hard after hours! KABOOM! 💥💥💥 Movers: $HUBC $SPHL $CMND 💵
0 · Reply
StocksandSuds
StocksandSuds Jun. 5 at 8:25 PM
$CMND still rock solid holding the line! Build baby build.
0 · Reply
topstockalerts
topstockalerts Jun. 5 at 8:02 PM
$CMND the action here feels constructive
0 · Reply